Personal profile

researchinterests

My research focuses on two major areas: 1) Cancer therapy: T-oligo: My cancer therapy research focuses on developing novel targeted therapies using T-oligo. We have found T-oligo (nucleotides homologous to the telomere overhang) to be therapeutically effective in lung cancer and melanoma cells and pre-established tumor xenografts by inducing apoptosis and senescence. We are currently attempting to deliver T-oligo as a nanoparticle complexed with a cationic peptide to melanoma tumors in mice. Lung Cancer: My project on lung cancer aims to unravel the mechanism of EGFR/c-Met tyrosine kinase inhibitor (TKI) resistance in Non-Small Cell lung cancer by studying the signaling pathways in resistant and parental NSCLC cell lines with and without EGFR TK mutations. Recent studies in our lab demonstrate activation of alternative signaling pathways in resistant cell lines which can be targeted along with EGFR and c-Met pathways to overcome or delay the TKI resistance. Currently, we are also investigating the role of epithelial mesenchymal transition in the development of resistance in NSCLC. Our translational research focuses on identifying the role of biomarkers EGFR/c-Met and key proteins from the mTOR and Wnt signaling pathways, in prognosis of NSCLC patients using immunohistochemistry. Melanoma: My cancer research also focuses on melanoma, where we have successfully evaluated the role of c-Met as a molecular target in melanoma. We are currently investigating the mechanism and TKI combination therapies to overcome c-Met and BRAF resistance in wild type and melanoma cell lines with a BRAF mutation. 2) Role of FTO in obesity: This project aims at identifying the role of FTO in promoting obesity in humans. We have downregulated FTO with siRNA and using a microarray studied affected genes. We have constructed a pathway from the microarray data and are currently identifying key targets. We are investigating the mechanism of how FTO induces obesity. Our recent studies indicate that FTO modulates intracellular energy levels and downstream signaling mechanisms which control energy intake and metabolism.

trainingexperience

1989Ph.D., Biochemistry at All India Institute of Medical Sciences, New Delhi, India
1980M.Phil., Molecular Biology and Biochemistry at University of Delhi, Delhi, India
1979M.Sc., Molecular Biology and Biochemistry at University of Delhi, Delhi, India

trainingexperience

1989Ph.D., Biochemistry at All India Institute of Medical Sciences, New Delhi, India
1980M.Phil., Molecular Biology and Biochemistry at University of Delhi, Delhi, India
1979M.Sc., Molecular Biology and Biochemistry at University of Delhi, Delhi, India

researchinterests

My research focuses on two major areas: 1) Cancer therapy: T-oligo: My cancer therapy research focuses on developing novel targeted therapies using T-oligo. We have found T-oligo (nucleotides homologous to the telomere overhang) to be therapeutically effective in lung cancer and melanoma cells and pre-established tumor xenografts by inducing apoptosis and senescence. We are currently attempting to deliver T-oligo as a nanoparticle complexed with a cationic peptide to melanoma tumors in mice. Lung Cancer: My project on lung cancer aims to unravel the mechanism of EGFR/c-Met tyrosine kinase inhibitor (TKI) resistance in Non-Small Cell lung cancer by studying the signaling pathways in resistant and parental NSCLC cell lines with and without EGFR TK mutations. Recent studies in our lab demonstrate activation of alternative signaling pathways in resistant cell lines which can be targeted along with EGFR and c-Met pathways to overcome or delay the TKI resistance. Currently, we are also investigating the role of epithelial mesenchymal transition in the development of resistance in NSCLC. Our translational research focuses on identifying the role of biomarkers EGFR/c-Met and key proteins from the mTOR and Wnt signaling pathways, in prognosis of NSCLC patients using immunohistochemistry. Melanoma: My cancer research also focuses on melanoma, where we have successfully evaluated the role of c-Met as a molecular target in melanoma. We are currently investigating the mechanism and TKI combination therapies to overcome c-Met and BRAF resistance in wild type and melanoma cell lines with a BRAF mutation. 2) Role of FTO in obesity: This project aims at identifying the role of FTO in promoting obesity in humans. We have downregulated FTO with siRNA and using a microarray studied affected genes. We have constructed a pathway from the microarray data and are currently identifying key targets. We are investigating the mechanism of how FTO induces obesity. Our recent studies indicate that FTO modulates intracellular energy levels and downstream signaling mechanisms which control energy intake and metabolism.

External positions

Associate Professor , University of Illinois, Rockford College of Medicine

2014 → …

Assistant Professor , University of Illinois, Rockford College of Medicine

20082014

Research Associate, UIC

20032007

Research Associate, Boston University Medical Centre

19982003

Assistant Researcher, University of Arizona Health Sciences Center

19971998

Research Associate, Fox Chase Cancer Center

19961997

Post Doc, The Wistar Institute of Anatomy and Biology, Affiliated with Univ of Pennsylvania, PA

19941996

Scientist, Dept. of Dermatology, Academic Medical, Univ. of Amsterdam

19901994

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

Therapeutics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Telomere Medicine & Life Sciences
Melanoma Medicine & Life Sciences
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Cells Chemical Compounds
Oligonucleotides Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2003 2016

Synergism of c-Met and EGFR pathways: their therapeutic role in lung cancer

Puri, N.

9/6/128/31/16

Project: Research projectExploratory/Developmental Grants

The Effect of the Telomere 3' Overhang DNA on Melanoma.

Puri, N.

7/15/036/30/07

Project: Research projectSmall Research Grants

Research Output 1987 2017

  • 1281 Citations
  • 17 h-Index
  • 36 Article
  • 1 Review article
3 Citations

Treating cancer by targeting telomeres and telomerase

Ivancich, M., Schrank, Z., Wojdyla, L., Leviskas, B., Kuckovic, A., Sanjali, A. & Puri, N. Mar 1 2017 In : Antioxidants. 6, 1, 15

Research output: Research - peer-reviewReview article

Telomerase
Telomere
Neoplasms
Cells
DNA
3 Citations

Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer

Rastogi, I., Rajanna, S., Webb, A., Chhabra, G., Foster, B., Webb, B. & Puri, N. Sep 2 2016 In : Biochemical and Biophysical Research Communications. 477, 4, p. 937-944 8 p.

Research output: Research - peer-reviewArticle

Epithelial-Mesenchymal Transition
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Cells
Cadherins

Current molecularly targeting therapies in NSCLC and melanoma

Rajanna, S., Rastogi, I., Wojdyla, L., Furo, H., Kulesza, A., Lin, L., Sheu, B., Frakes, M., Ivanovich, M. & Puri, N. Jul 1 2015 In : Anti-Cancer Agents in Medicinal Chemistry. 15, 7, p. 856-868 13 p.

Research output: Research - peer-reviewArticle

Non-Small Cell Lung Carcinoma
Melanoma
Therapeutics
Neoplasms
Biomarkers
12 Citations

Mechanism of resistance and novel targets mediating resistance to EGFR and c-Met tyrosine kinase inhibitors in non-small cell lung cancer

Botting, G. M., Rastogi, I., Chhabra, G., Nlend, M. & Puri, N. Aug 24 2015 In : PLoS One. 10, 8, e0136155

Research output: Research - peer-reviewArticle

lung neoplasms
resistance mechanisms
tyrosine
phosphotransferases (kinases)
cells

Current molecularly targeted therapies against EGFR for cancer

Rastogi, I., Rajanna, S. & Puri, N. Jan 1 2014 In : Journal of Cancer Science and Therapy. 6, 2, e131

Research output: Research - peer-reviewArticle

Prizes

18th international pigment cell conference presenter

Neelu Puri (Recipient), 1800

Prize: Prize (including medals and awards)

Best Poster Award on 13th annual research day

Neelu Puri (Recipient), 1800

Prize: Prize (including medals and awards)

Faculty Support Scholarship Award

Neelu Puri (Recipient), 2009

Prize: Prize (including medals and awards)

Faculty Support Scholarship Award

Neelu Puri (Recipient), 2013

Prize: Prize (including medals and awards)

Faculty Support Scholarship Award,

Neelu Puri (Recipient), 2012

Prize: Prize (including medals and awards)